乳腺癌易感基因2抗體 返回列表頁

英文名稱 FANCB/BRCA2
中文名稱 乳腺癌易感基因2抗體
別    名 BRCA 2; BRCA1/BRCA2 containing complex subunit 2; BRCC 2; BRCC2; Breast and ovarian cancer susceptibility gene early onset; Breast cancer 2 early onset; Breast Cancer 2 tumor suppressor; Breast cancer susceptibility protein BRCA2; Breast cancer type 2 susceptibility protein; FACD; FAD 1; FAD; FAD1; FANCB; FANCD 1; FANCD; FANCD1; Fanconi anemia complementation group D1; Fanconi anemia group D1 protein; OTTHUMP00000018803; OTTHUMP00000042401.
乳腺癌易感基因2抗體    
說 明 書 0.1ml  0.2ml  
研究領(lǐng)域 腫瘤  細(xì)胞生物  免疫學(xué)  
抗體來源 Rabbit
克隆類型 Polyclonal
交叉反應(yīng) Human, Mouse, Rat, Chicken, Dog, Cow, Horse, Rabbit, 
產(chǎn)品應(yīng)用 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 （石蠟切片需做抗原修復(fù)）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量 384kDa
性    狀 Lyophilized or Liquid
濃    度 1mg/1ml
免 疫 原 KLH conjugated synthetic peptide derived from human BRCA2
亞    型 IgG
純化方法 affinity purified by Protein A
儲(chǔ) 存 液 0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
產(chǎn)品介紹 background:
The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity; they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group B. Alternative splicing results in two transcript variants encoding the same protein. [provided by RefSeq, Jul 2008]

Function:
Involved in double-strand break repair and/or homologous recombination. Binds RAD51 and potentiates recombinational DNA repair by promoting assembly of RAD51 onto single-stranded DNA (ssDNA). Acts by targeting RAD51 to ssDNA over double-stranded DNA, enabling RAD51 to displace replication protein-A (RPA) from ssDNA and stabilizing RAD51-ssDNA filaments by blocking ATP hydrolysis. May participate in S phase checkpoint activation. Binds selectively to ssDNA, and to ssDNA in tailed duplexes and replication fork structures. In concert with NPM1, regulates centrosome duplication.

Subunit:
Monomer and dimer. Interacts with RAD51; regulates RAD51 recruitment and function at sites of DNA repair. Interacts with DSS1. Interacts with both nonubiquitinated and monoubiquitinated FANCD2; this complex also includes XRCC3 and phosphorylated FANCG. Interacts with WDR16. Interacts with USP11. Interacts with DMC1. Part of a trimeric complex containing BRCA1, BRCA2 and PALB2. Interacts with PALB2. Interacts with BRCA1 only in the presence of PALB2 which serves as the bridging protein. Interacts with ROCK2 and NPM1.

Subcellular Location:
Nuclear protein.

Tissue Specificity:
Highest levels of expression in breast and thymus, with slightly lower levels in lung, ovary and spleen.

Post-translational modifications:
Phosphorylated by ATM upon irradiation-induced DNA damage. Phosphorylation by CHEK1 and CHEK2 regulates interaction with RAD51. Phosphorylation at Ser-3291 by CDK1 and CDK2 is low in S phase when recombination is active, but increases as cells progress towards mitosis; this phosphorylation prevents homologous recombination-dependent repair during S phase and G2 by inhibiting RAD51 binding.
Ubiquitinated in the absence of DNA damage; this does not lead to proteasomal degradation. In contrast, ubiquitination in response to DNA damage leads to proteasomal degradation.

DISEASE:
Defects in BRCA2 are a cause of susceptibility to breast cancer (BC). A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case. Defects in BRCA2 are the cause of pancreatic cancer type 2 (PNCA2) [MIM:613347]. It is a malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.

Similarity:
Contains 8 BRCA2 repeats.

Gene ID:
2187

Database links:

Entrez Gene: 2187 Human

Omim: 300515 Human

SwissProt: Q8NB91 Human

Unigene: 554740 Human

xy-11195R BAF53b肌動(dòng)蛋白樣蛋白6B抗體
xy-11318R Ataxin 7脊髓小腦共濟(jì)失調(diào)蛋白7抗體
xy-11329R phospho-c-Abl (Tyr70)磷酸化非受體酪氨酸激酶c-Abl抗體
xy-11334R APBA1β淀粉樣前體蛋白結(jié)合蛋白1抗體（X11α）
xy-4892R Apolipoprotein E載脂蛋白E抗體
xy-4821R AFP甲胎蛋白AFP抗體
xy-9847R AE2陰離子交換蛋白2抗體
xy-9848R Aconitase 1鐵調(diào)節(jié)蛋白1抗體
xy-9108R ATAD3A三磷酸腺苷酶家族蛋白3A抗體
xy-1354R APOJ載脂蛋白J抗體
xy-1570R APOH載脂蛋白H抗體
xy-7621R ART4二磷酸腺苷核糖基轉(zhuǎn)移酶4抗體
xy-9082R AKIRIN2AKIRIN2蛋白抗體
xy-9304R ARL8BADP核糖基化樣因子8B抗體
xy-9110R ATAD2三磷酸腺苷酶家族蛋白2抗體
xy-9081R AKIRIN1AKIRIN1蛋白抗體
xy-9325R ASZ1錨定蛋白樣蛋白1抗體
xy-6875R Adenylate kinase 2腺苷酸激酶2抗體
xy-5151R Acrosin精子頂體前體蛋白抗體
xy-9093R AIM1L黑色素瘤缺失樣蛋白1抗體
xy-9096R AER61未知糖基化轉(zhuǎn)移酶AER61抗體
xy-0110R FE65鐵蛋白Fe65抗體
xy-2903R ARHI抑癌基因ras同源家族1抗體
xy-3569R AP2 alpha轉(zhuǎn)錄激活蛋白2α/TFAP2α/AP-2α抗體
xy-2040R ANP心鈉素抗體
xy-1603R AARS2丙氨酰tRNA合成酶2抗體
xy-1381R AKAP12絲氨酸抑制蛋白激酶C底物抗體
xy-0968R Alpha-Synuclein核突觸蛋白α抗體
xy-1384R APG4B自噬相關(guān)蛋白4B抗體

Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.